ORIC Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ORIC Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-112.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 83% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-33.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 65% of Healthcare companies in United States.
Cash Cushion Ratio
+20%Cash, after subtracting all debt, equals 20% of its market value (net cash).
Higher than 63% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
ORIC Pharmaceuticals, Inc. made a loss over the last year. ORIC Pharmaceuticals, Inc. owes $0.06 for every $1 it owns. ORIC Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossORIC Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.71The share price is 3.71 times ORIC Pharmaceuticals, Inc.'s book value per share, higher than 63% of Healthcare companies in United States.
Market cap
$1.4 BThe total market value of all of ORIC Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 68% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$381 MWhat ORIC Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.68Net worth divided by the number of shares. The share price of $13.63 is 3.7 times this, which is the P/B above.
Return on equity (ROE)
-39.8%ORIC Pharmaceuticals, Inc. lost 39.8% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
Owes vs Owns
0.06×ORIC Pharmaceuticals, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneORIC Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossORIC Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashORIC Pharmaceuticals, Inc. held $278 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ORIC Pharmaceuticals, Inc.: $1.4 B ÷ $381 M (30 Jun 2026) = 3.7.
What is ORIC Pharmaceuticals, Inc.'s return on equity?
ORIC Pharmaceuticals, Inc. lost 39.8% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
How much does ORIC Pharmaceuticals, Inc. owe compared with what it owns?
ORIC Pharmaceuticals, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does ORIC Pharmaceuticals, Inc. pay a dividend?
No. ORIC Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.